The total return over the past 12 months is +12.72% vs. +16.94% for the S&P 500. So far it's up +9.49% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +12.72% | (21.91%) | (42.72%) | N/A | N/A | N/A |
| Total Return CAGR | +12.72% | (21.91%) | (42.72%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | +215.24% | (34.47%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Allogene Therapeutics, Inc. (ALLO)
| Year | Start price | End price | ALLO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.37 | $1.50 | +9.49% | +14.51% | (5.02%) |
| 2025 | $2.13 | $1.37 | (35.68%) | +17.72% | (53.40%) |
| 2024 | $3.21 | $2.13 | (33.64%) | +24.89% | (58.53%) |
| 2023 | $6.29 | $3.21 | (48.97%) | +26.19% | (75.16%) |
| 2022 | $14.92 | $6.29 | (57.84%) | (18.17%) | (39.67%) |
| 2021 | $25.24 | $14.92 | (40.89%) | +28.74% | (69.63%) |
| 2020 | $25.98 | $25.24 | (2.85%) | +18.37% | (21.22%) |
| 2019 | $26.93 | $25.98 | (3.53%) | +31.22% | (34.75%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
